Hybrid antibodies in cancer diagnosis and therapy

S. Menard, S. Canevari, M. I. Colnaghi

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Monoclonal Antibodies (MAbs) represent a promising tool for cancer diagnosis and therapy. Administration of MAbs alone or conjugated to cytotoxic agents has been attempted but has significant limitations. Another potentially effective approach is the use of bispecific or bifunctional antibodies where the capacity to recognize the tumor cell and the toxic agent or lymphocyte activation molecule are united in one MAb. The hybrid molecule can be produced by chemical linkage between the two parental antibodies, or alternatively by a biological approach that consists in the fusion of the two selected hybridomas. In the resulting quadroma cell the hybridoma immunoglobulin chains recombine randomly to form the bifunctional MAb. In different in vitro and in vivo models, bifunctional MAbs against tumor and CD3 at nanomolar concentration has been shown to promote tumor cell killing by cytotoxic T cells. Specific localization of chemotherapeutic drugs in xenografted tumors has been demonstrated in mice pretreated with hybrid MAbs. The advantages of the hybrid MAb approach are that it should reduce the MAb biodistribution problem and that it involves no chemical manipulation between the functional agent and the MAb molecules.

Original languageEnglish
Pages (from-to)131-134
Number of pages4
JournalInternational Journal of Biological Markers
Volume4
Issue number3
Publication statusPublished - 1989

Fingerprint

Tumors
Bispecific Antibodies
Monoclonal Antibodies
Antibodies
Molecules
Hybridomas
Neoplasms
Immunoglobulin Subunits
Cells
T-cells
Lymphocytes
Poisons
Cytotoxins
Therapeutics
Lymphocyte Activation
Fusion reactions
Chemical activation
T-Lymphocytes
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Biochemistry
  • Immunology

Cite this

Menard, S., Canevari, S., & Colnaghi, M. I. (1989). Hybrid antibodies in cancer diagnosis and therapy. International Journal of Biological Markers, 4(3), 131-134.

Hybrid antibodies in cancer diagnosis and therapy. / Menard, S.; Canevari, S.; Colnaghi, M. I.

In: International Journal of Biological Markers, Vol. 4, No. 3, 1989, p. 131-134.

Research output: Contribution to journalArticle

Menard, S, Canevari, S & Colnaghi, MI 1989, 'Hybrid antibodies in cancer diagnosis and therapy', International Journal of Biological Markers, vol. 4, no. 3, pp. 131-134.
Menard, S. ; Canevari, S. ; Colnaghi, M. I. / Hybrid antibodies in cancer diagnosis and therapy. In: International Journal of Biological Markers. 1989 ; Vol. 4, No. 3. pp. 131-134.
@article{9ea9a1b5a14440178bdb8a10338cce40,
title = "Hybrid antibodies in cancer diagnosis and therapy",
abstract = "Monoclonal Antibodies (MAbs) represent a promising tool for cancer diagnosis and therapy. Administration of MAbs alone or conjugated to cytotoxic agents has been attempted but has significant limitations. Another potentially effective approach is the use of bispecific or bifunctional antibodies where the capacity to recognize the tumor cell and the toxic agent or lymphocyte activation molecule are united in one MAb. The hybrid molecule can be produced by chemical linkage between the two parental antibodies, or alternatively by a biological approach that consists in the fusion of the two selected hybridomas. In the resulting quadroma cell the hybridoma immunoglobulin chains recombine randomly to form the bifunctional MAb. In different in vitro and in vivo models, bifunctional MAbs against tumor and CD3 at nanomolar concentration has been shown to promote tumor cell killing by cytotoxic T cells. Specific localization of chemotherapeutic drugs in xenografted tumors has been demonstrated in mice pretreated with hybrid MAbs. The advantages of the hybrid MAb approach are that it should reduce the MAb biodistribution problem and that it involves no chemical manipulation between the functional agent and the MAb molecules.",
author = "S. Menard and S. Canevari and Colnaghi, {M. I.}",
year = "1989",
language = "English",
volume = "4",
pages = "131--134",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing Srl",
number = "3",

}

TY - JOUR

T1 - Hybrid antibodies in cancer diagnosis and therapy

AU - Menard, S.

AU - Canevari, S.

AU - Colnaghi, M. I.

PY - 1989

Y1 - 1989

N2 - Monoclonal Antibodies (MAbs) represent a promising tool for cancer diagnosis and therapy. Administration of MAbs alone or conjugated to cytotoxic agents has been attempted but has significant limitations. Another potentially effective approach is the use of bispecific or bifunctional antibodies where the capacity to recognize the tumor cell and the toxic agent or lymphocyte activation molecule are united in one MAb. The hybrid molecule can be produced by chemical linkage between the two parental antibodies, or alternatively by a biological approach that consists in the fusion of the two selected hybridomas. In the resulting quadroma cell the hybridoma immunoglobulin chains recombine randomly to form the bifunctional MAb. In different in vitro and in vivo models, bifunctional MAbs against tumor and CD3 at nanomolar concentration has been shown to promote tumor cell killing by cytotoxic T cells. Specific localization of chemotherapeutic drugs in xenografted tumors has been demonstrated in mice pretreated with hybrid MAbs. The advantages of the hybrid MAb approach are that it should reduce the MAb biodistribution problem and that it involves no chemical manipulation between the functional agent and the MAb molecules.

AB - Monoclonal Antibodies (MAbs) represent a promising tool for cancer diagnosis and therapy. Administration of MAbs alone or conjugated to cytotoxic agents has been attempted but has significant limitations. Another potentially effective approach is the use of bispecific or bifunctional antibodies where the capacity to recognize the tumor cell and the toxic agent or lymphocyte activation molecule are united in one MAb. The hybrid molecule can be produced by chemical linkage between the two parental antibodies, or alternatively by a biological approach that consists in the fusion of the two selected hybridomas. In the resulting quadroma cell the hybridoma immunoglobulin chains recombine randomly to form the bifunctional MAb. In different in vitro and in vivo models, bifunctional MAbs against tumor and CD3 at nanomolar concentration has been shown to promote tumor cell killing by cytotoxic T cells. Specific localization of chemotherapeutic drugs in xenografted tumors has been demonstrated in mice pretreated with hybrid MAbs. The advantages of the hybrid MAb approach are that it should reduce the MAb biodistribution problem and that it involves no chemical manipulation between the functional agent and the MAb molecules.

UR - http://www.scopus.com/inward/record.url?scp=0024350251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024350251&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 131

EP - 134

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 3

ER -